The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Structure and function of OprD protein in Pseudomonas aeruginosa: From antibiotic resistance to novel therapies
Open accessAbstract
Pseudomonas aeruginosa (P. aeruginosa) is a common pathogen isolated from patients with nosocomial infections. Due to its intrinsic and acquired antimicrobial resistance, limited classes of antibiotics can be used for the treatment of infection with P. aeruginosa. Of these, the carbapenems are very important; however, the occurrence of carbapenem-resistant strains is gradually increasing over time. Deficiency of the outer membrane protein OprD confers P. aeruginosa a basal level of resistance to carbapenems, especially to imipenem. Functional studies have revealed that loops 2 and 3 in the OprD protein contain the entrance and/or binding sites for imipenem. Therefore, any mutation in loop 2 and/or loop 3 that causes conformational changes could result in carbapenem resistance. OprD is also a common channel for some amino acids and peptides, and competition with carbapenems through the channel may also occur. Furthermore, OprD is a highly regulated protein at transcriptional and post-transcriptional levels by some metals, small bioactive molecules, amino acids, and efflux pump regulators. Because of its hypermutability and highly regulated properties, OprD is thought to be the most prevalent mechanism for carbapenem resistance in P. aeruginosa. Developing new strategies to combat infection with carbapenem-resistant P. aeruginosa lacking OprD is an ongoing challenge.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mutations of specific porins OprD involving conformational features cause carbapenem resistance, a serious challenge for medical treatment practices.234”
From Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics (2022) · cites this paper as [234]
In the citing paper
“Mutations of OprD in P. aeruginosa confers resistance to carbapenems234 and mutations of DNA gyrase (GyrA) causes resistance to quinolone antibiotics.257”
From Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics (2022) · cites this paper as [234]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
System, A. R. F. T. N. (2003) · American Journal of Infection Control · doi:10.1016/j.ajic.2003.09.002 · Cited by 2,915
System, A. R. F. T. N. (2004) · American Journal of Infection Control · doi:10.1016/j.ajic.2004.10.001 · Cited by 2,342
High Frequency of Hypermutable Pseudomonas aeruginosa in Cystic Fibrosis Lung Infection
Oliver, A., Cantón, R., Campo, P., Baquero, F., & Blázquez, J. (2000) · Science · doi:10.1126/science.288.5469.1251 · Cited by 1,465
Comparative Review of the Carbapenems
Zhanel, G. G., Wiebe, R., Dilay, L., Thomson, K., Rubinstein, E., Hoban, D. J., Noreddin, A. M., & Karlowsky, J. A. (2007) · Drugs · doi:10.2165/00003495-200767070-00006 · Cited by 652
Ko¨hler, T., Michéa‐Hamzehpour, M., Henze, U., Gotoh, N., Kocjancic Curty, L., & Pechère, J. (1997) · Molecular Microbiology · doi:10.1046/j.1365-2958.1997.2281594.x · Cited by 549
Quale, J., Bratu, S., Gupta, J., & Landman, D. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.5.1633-1641.2006 · Cited by 409
Perron, K., Caille, O., Rossier, C., van Delden, C., Dumas, J.-L., & Köhler, T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312080200 · Cited by 358
Köhler, T., Epp, S. F., Curty, L. K., & Pechère, J.-C. (1999) · Journal of Bacteriology · doi:10.1128/jb.181.20.6300-6305.1999 · Cited by 302
Trias, J., & Nikaido, H. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.1.52 · Cited by 291
Emergence of Resistance to Imipenem During Therapy for Pseudomonas aeruginosa Infections
Quinn, J. P., Dudek, E. J., DiVincenzo, C. A., Lucks, D. A., & Lerner, S. A. (1986) · Journal of Infectious Diseases · doi:10.1093/infdis/154.2.289 · Cited by 276
Cited by
Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies
Pang, Z., Raudonis, R., Glick, B. R., Lin, T.-J., & Cheng, Z. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.11.013 · Cited by 2,306
Qin, S., Xiao, W., Zhou, C., Pu, Q., Deng, X., Lan, L., Liang, H., Song, X., & Wu, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01056-1 · Cited by 1,703
Peterson, E., & Kaur, P. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02928 · Cited by 1,006
New β-Lactam–β-Lactamase Inhibitor Combinations
Yahav, D., Giske, C. G., Grāmatniece, A., Abodakpi, H., Tam, V. H., & Leibovici, L. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00115-20 · Cited by 521
Verdial, C., Serrano, I., Tavares, L., Gil, S., & Oliveira, M. (2023) · Biomedicines · doi:10.3390/biomedicines11041221 · Cited by 71
Metadata
- Authors
- Li, H., Luo, Y.-F., Williams, B. J., Blackwell, T. S., & Xie, C.-M.
- Venue
- International Journal of Medical Microbiology
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 302
- Issue
- 2
- Pages
- 63-68
- ISSN
- 1438-4221 (ISSN-L)
- OpenAlex
- W2044584162
- Cited by
- 266
- References
- 45
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Structure and function of OprD protein in Pseudomonas aeruginosa: From antibiotic resistance to novel therapies. https://app.cochat.ai/papers/10.1016/j.ijmm.2011.10.001
- The paper
- Li, H., Luo, Y.-F., Williams, B. J., Blackwell, T. S., & Xie, C.-M. (2012). Structure and function of OprD protein in Pseudomonas aeruginosa: From antibiotic resistance to novel therapies. International Journal of Medical Microbiology. https://doi.org/10.1016/j.ijmm.2011.10.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.